{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:45:55Z","timestamp":1790520355937,"version":"4.1.0"},"reference-count":93,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:p>Allergic contact dermatitis is a common disease within the family of delayed-type hypersensitivity reactions. In more severe cases of allergic contact dermatitis, topical steroids may prove insufficient, and systemic therapeutic agents are often used. Even when systemic therapies such as cyclosporine lead to improvement, withdrawal of these agents is challenging and can lead to undesirable morbidities. Currently, there are no systemic treatments indicated for the treatment of widespread recalcitrant contact dermatitis. This review discusses the targets of in-use off-label systemic medications and potential therapeutics in the pipeline.<\/jats:p>","DOI":"10.1097\/der.0000000000000435","type":"journal-article","created":{"date-parts":[[2019,1,13]],"date-time":"2019-01-13T20:49:29Z","timestamp":1547412569000},"page":"46-53","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":33,"title":["Systemic Treatments for Allergic Contact Dermatitis"],"prefix":"10.1177","volume":"30","author":[{"given":"Calvin T.","family":"Sung","sequence":"first","affiliation":[{"name":"From the, *School of Medicine, University of California, Riverside"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"McGowan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Loma Linda University, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Machler","sequence":"additional","affiliation":[{"name":"Ronald O. Perelman Department of Dermatology, New York University, New York City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon E.","family":"Jacob","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Loma Linda University, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,2,1]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2009.01695.x"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000387"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1972.tb01895.x"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.2310\/6620.2008.07040"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-1873.2004.00340.x"},{"key":"e_1_3_1_7_2","unstructured":"Sung CT McGowan MA Machler BC et al. Drugs@FDA: FDA approved drug product. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&applno=011719. Accessed June1 2018."},{"issue":"6","key":"e_1_3_1_8_2","article-title":"The anti-inflammatory mechanism of methotrexate","volume":"92","author":"Cronstein BN","year":"1993","unstructured":"Cronstein BN, , Naime D, , Ostad E. The anti-inflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest, 1993; 92(6):2675\u20131682.","journal-title":"Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest"},{"key":"e_1_3_1_9_2","first-page":"168","article-title":"Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis","volume":"65","author":"Tian H","year":"2007","unstructured":"Tian H, , Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis, 2007; 65:168\u2013173.","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12612745"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/cod.12925"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2006.00950.x"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1994.tb03874.x"},{"key":"e_1_3_1_14_2","unstructured":"Pubchem. Azathioprine. Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/. Accessed June1 2018."},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1998.00307.x"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.19713"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.104679"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.44299"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/cod.12691"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09080.x"},{"key":"e_1_3_1_21_2","first-page":"75","article-title":"Long-term safety and toxicity of azathioprine in patients with air-borne contact dermatitis","volume":"67","author":"Kaushal K","year":"2001","unstructured":"Kaushal K, , Manchanda Y. Long-term safety and toxicity of azathioprine in patients with air-borne contact dermatitis. Indian J Dermatol Venereol Leprol, 2001; 67:75\u201377.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"e_1_3_1_22_2","first-page":"715","article-title":"Mycophenolate mofetil in severe atopic dermatitis: a review","volume":"15","author":"Prussick L","year":"2016","unstructured":"Prussick L, , Plotnikova N, , Gottlieb A. Mycophenolate mofetil in severe atopic dermatitis: a review. J Drugs Dermatol, 2016; 15:715\u2013718.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_1_23_2","first-page":"9672718","article-title":"Enhancement of mycophenolate mofetil permeation for topical use by eucalyptol and N-methyl-2-pyrrolidone","volume":"2016","author":"Amnuaikit T","year":"2016","unstructured":"Amnuaikit T, , Songkram C, , Pinsuwan S. Enhancement of mycophenolate mofetil permeation for topical use by eucalyptol and N-methyl-2-pyrrolidone. Scientifica (Cairo), 2016; 2016:9672718.","journal-title":"Scientifica (Cairo)"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000074"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12348507"},{"key":"e_1_3_1_26_2","first-page":"156","article-title":"IL-31 and IL-33 circulating levels in allergic contact dermatitis","volume":"47","author":"Guarneri F","year":"2015","unstructured":"Guarneri F, , Minciullo PL, , Mannucci C, et al. IL-31 and IL-33 circulating levels in allergic contact dermatitis. Eur Ann Allergy Clin Immunol, 2015; 47:156\u2013158.","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"e_1_3_1_27_2","first-page":"428","article-title":"Interleukin 33 is induced by tumor necrosis factor alpha and interferon gamma in keratinocytes and contributes to allergic contact dermatitis","volume":"23","author":"Taniguchi K","year":"2013","unstructured":"Taniguchi K, , Yoshizaki A, , Yanaba K, et al. Interleukin 33 is induced by tumor necrosis factor alpha and interferon gamma in keratinocytes and contributes to allergic contact dermatitis. J Investig Allergol Clin Immunol, 2013; 23:428\u2013434.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.25"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.09.036"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e3282ef869e"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1021\/tx049688"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(97)80019-9"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-9-19"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.2340\/0001555556135138"},{"key":"e_1_3_1_35_2","first-page":"e112","article-title":"Contact dermatitis and interferon-gamma dependent chemokines","volume":"167","author":"Fallahi P","year":"2016","unstructured":"Fallahi P, , Ruffilli I. Contact dermatitis and interferon-gamma dependent chemokines. Clin Ter, 2016; 167:e112\u2013e116.","journal-title":"Clin Ter"},{"key":"e_1_3_1_36_2","unstructured":"Pubchem. Cyclosporine. 2018. Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/."},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04636.x"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.07.007"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2007.01209.x"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.2340\/0001555576371376"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13253"},{"key":"e_1_3_1_42_2","first-page":"543","article-title":"Exacerbation of allergic contact dermatitis during immunosuppression with cyclosporine A","volume":"145","author":"Prignano F","year":"2010","unstructured":"Prignano F, , Bonciolini V, , Bonciani D, et al. Exacerbation of allergic contact dermatitis during immunosuppression with cyclosporine A. G Ital Dermatol Venereol, 2010; 145:543\u2013546.","journal-title":"G Ital Dermatol Venereol"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-9740.2004.03590.x"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13918"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.020"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-015-0150-4"},{"key":"e_1_3_1_47_2","first-page":"341","article-title":"A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis","volume":"11","author":"Volf EM","year":"2012","unstructured":"Volf EM, , Au SC, , Dumont N, et al. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol, 2012; 11:341\u2013346.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000243"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.2287"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/cod.12769"},{"key":"e_1_3_1_51_2","first-page":"257","article-title":"Dermal tumour necrosis factor-alpha induces dendritic cell migration to draining lymph nodes, and possibly provides one stimulus for Langerhans' cell migration","volume":"75","author":"Cumberbatch M","year":"1992","unstructured":"Cumberbatch M, , Kimber I. Dermal tumour necrosis factor-alpha induces dendritic cell migration to draining lymph nodes, and possibly provides one stimulus for Langerhans' cell migration. Immunology, 1992; 75:257\u2013263.","journal-title":"Immunology"},{"key":"e_1_3_1_52_2","first-page":"31","article-title":"Tumour necrosis factor-alpha is required for accumulation of dendritic cells in draining lymph nodes and for optimal contact sensitization","volume":"84","author":"Cumberbatch M","year":"1995","unstructured":"Cumberbatch M, , Kimber I. Tumour necrosis factor-alpha is required for accumulation of dendritic cells in draining lymph nodes and for optimal contact sensitization. Immunology, 1995; 84:31\u201335.","journal-title":"Immunology"},{"key":"e_1_3_1_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0029(20000801)50:3<216::AID-JEMT5>3.0.CO;2-Q"},{"key":"e_1_3_1_54_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0536.2003.480208.x"},{"key":"e_1_3_1_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri3150"},{"key":"e_1_3_1_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2005.tb00794.x"},{"key":"e_1_3_1_57_2","unstructured":"2018. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/103772s5377lbl.pdf."},{"key":"e_1_3_1_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000056"},{"key":"e_1_3_1_59_2","doi-asserted-by":"publisher","DOI":"10.3109\/09546639609089541"},{"key":"e_1_3_1_60_2","doi-asserted-by":"publisher","DOI":"10.1177\/205873920601900125"},{"key":"e_1_3_1_61_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.9.1258"},{"key":"e_1_3_1_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.016"},{"key":"e_1_3_1_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.10.044"},{"key":"e_1_3_1_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0503-x"},{"key":"e_1_3_1_65_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.141.12.4217"},{"key":"e_1_3_1_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02719.x"},{"key":"e_1_3_1_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2006.02330.x"},{"key":"e_1_3_1_68_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703054"},{"key":"e_1_3_1_69_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1999.00550.x"},{"key":"e_1_3_1_70_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1998.tb05634.x"},{"key":"e_1_3_1_71_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.180.5.1961"},{"key":"e_1_3_1_72_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.3.1093"},{"key":"e_1_3_1_73_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.3.1001"},{"key":"e_1_3_1_74_2","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200105)31:5<1582::AID-IMMU1582>3.0.CO;2-M"},{"key":"e_1_3_1_75_2","first-page":"2698","article-title":"IL-4 is essential for the systemic transfer of delayed hypersensitivity by T cell lines","volume":"152","author":"Dieli F","year":"1994","unstructured":"Dieli F, , Asherson GL, , Romano GC, et al. IL-4 is essential for the systemic transfer of delayed hypersensitivity by T cell lines. Role of gamma\/delta cells. J Immunol, 1994; 152:2698\u20132704.","journal-title":"Role of gamma\/delta cells. J Immunol"},{"key":"e_1_3_1_76_2","first-page":"404","article-title":"Interleukin-4 is a critical cytokine in contact sensitivity","volume":"84","author":"Salerno A","year":"1995","unstructured":"Salerno A, , Dieli F, , Sireci G, et al. Interleukin-4 is a critical cytokine in contact sensitivity. Immunology, 1995; 84:404\u2013409.","journal-title":"Immunology"},{"key":"e_1_3_1_77_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.3.1395"},{"key":"e_1_3_1_78_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1996.845537.x"},{"key":"e_1_3_1_79_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.1999.00844.x"},{"key":"e_1_3_1_80_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3083.1997.d01-402.x"},{"key":"e_1_3_1_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.07.015"},{"key":"e_1_3_1_82_2","doi-asserted-by":"publisher","DOI":"10.1159\/000086659"},{"key":"e_1_3_1_83_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.149.11.3503"},{"key":"e_1_3_1_84_2","first-page":"363","article-title":"Gamma delta T cells in normal murine spleen assist immunized alpha beta T cells in the adoptive cell transfer of contact sensitivity: effect of Bordetella pertussis","volume":"107","author":"Askenase PW","year":"1995","unstructured":"Askenase PW, , Ptak W, , Szczepanik M. Gamma delta T cells in normal murine spleen assist immunized alpha beta T cells in the adoptive cell transfer of contact sensitivity: effect of Bordetella pertussis. Cyclophosphamide, and antisuppressor T cell monoclonal antibodies. Int Arch Allergy Immunol, 1995; 107:363.","journal-title":"Cyclophosphamide, and antisuppressor T cell monoclonal antibodies. Int Arch Allergy Immunol"},{"key":"e_1_3_1_85_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2001.01570.x"},{"key":"e_1_3_1_86_2","unstructured":"Dupixent (dupilumab) injection. 2017. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761055lbl.pdf."},{"key":"e_1_3_1_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.10.013"},{"key":"e_1_3_1_88_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000346"},{"key":"e_1_3_1_89_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000409"},{"key":"e_1_3_1_90_2","article-title":"Dupilumab use in allergic contact dermatitis","author":"Machler BC","year":"2018","unstructured":"Machler BC, , Sung CT, , Darwin E, et al. Dupilumab use in allergic contact dermatitis. J Am Acad Dermatol, 2018. pii: S0190-9622(18)32345\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_1_91_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12701"},{"key":"e_1_3_1_92_2","article-title":"Recall dermatitis at patch test sites in an atopic dermatitis patient treated with dupilumab","author":"Collantes-Rodriguez C","year":"2018","unstructured":"Collantes-Rodriguez C, , Jimenez-Gallo D, , Ossorio-Garcia L, et al. Recall dermatitis at patch test sites in an atopic dermatitis patient treated with dupilumab. Contact Dermatitis, 2018. Epub ahead of print.","journal-title":"Contact Dermatitis"},{"key":"e_1_3_1_93_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000357"},{"key":"e_1_3_1_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.08.027"}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1097\/DER.0000000000000435","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1097\/DER.0000000000000435","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1097\/DER.0000000000000435","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:04:44Z","timestamp":1777399484000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1097\/DER.0000000000000435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2,1]]}},"alternative-id":["10.1097\/DER.0000000000000435"],"URL":"https:\/\/doi.org\/10.1097\/der.0000000000000435","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,1]]}}}